Earnings Releases·Oct 29, 2026, 6:43 AM ET

Merck & Co., Inc. — Third Quarter 2026 Earnings Summary

Worldwide sales reached $18.1 billion, a 5% increase year-over-year, while GAAP net income and EPS declined 12% to $5.1 billion and $2.04 respectively, impacted by higher amortization, restructuring, and a $0.12 per share one-time charge for the SciBrunch agreement.
The company raised full-year 2026 guidance, narrowing the worldwide sales range to $66.8–$67.3 billion and increasing Non-GAAP EPS guidance to $2.77–$2.82, reflecting a positive foreign exchange impact of approximately 1% on sales and $0.15 per share.
Pharmaceutical sales grew 4% year-over-year to $16.3 billion, driven by 6% growth in KEYTRUDA ($8.6 billion), a 93% surge in WINREVAIR ($694 million), and 14% growth in GARDASIL ($2.0 billion), offset by significant declines in JANUVIA, BRIDION, and LAGEVRIO due to generic competition.
Strategic developments include the entry into an exclusive global license agreement with SciBrunch for MK-2690, FDA acceptance of BLAs for sacituzumab tirumotecan and ENFLONSIA, and the voluntary withdrawal of the I-DXd BLA for small cell lung cancer.